MedTrace Logo

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

NCT01671787 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2018-10-23

No results posted yet for this study

Summary

This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).

Conditions

Interventions

DRUG

GS-7340

Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.

DRUG

Tenofovir disoproxil fumarate

Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy

Sponsors & Collaborators

Principal Investigators

  • John Flaherty, MD · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States
  • Australia
  • Canada
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01671787 on ClinicalTrials.gov